Skip to main navigation Skip to search Skip to main content

Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts

  • Roben G. Gieling
  • , Muhammad Babur
  • , Lupti Mamnani
  • , Natalie Burrows
  • , Brian A. Telfer
  • , Fabrizio Carta
  • , Jean Yves Winum
  • , Andrea Scozzafava
  • , Claudiu T. Supuran
  • , Kaye J. Williams

    Research output: Contribution to journalArticlepeer-review

    Abstract

    A panel of compounds belonging to the underexposed sulfamate class of carbonic anhydrase (CA, EC 4.2.1.1) inhibitors was generated that displayed high specificity at nanomolar levels for the tumor-associated CA IX/XII isoforms. Three of the specific CA IX/XII inhibitors showed a positive response in in vitro assays for tumor cell migration and spreading. One of them, 4-(3′-(3″,5″-dimethylphenyl)ureido)phenyl sulfamate (S4), was taken forward into the orthotopic MDA-MB-231 (breast carcinoma) model in mice. Treatment with a 10 mg/kg maintenance dosage of S4 given daily on a "5 days on, 2 days off" regimen reduced metastatic tumor burden in the lung while not affecting primary tumor growth or mouse condition. CA inhibitors of the sulfamate class specifically targeting the tumor-associated isoforms are potential candidates in antimetastatic therapy. © 2012 American Chemical Society.
    Original languageEnglish
    Pages (from-to)5591-5600
    Number of pages9
    JournalJournal of Medicinal Chemistry
    Volume55
    Issue number11
    DOIs
    Publication statusPublished - 14 Jun 2012

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts'. Together they form a unique fingerprint.

    Cite this